The Role of Amyloids in Neurodegenerative Diseases: Current Insights and Future Perspectives

Dear Colleagues,

It is well known that amyloid accumulation is a key pathological hallmark of multiple neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, or amyotrophic lateral sclerosis, among others.

The toxic potential of amyloid aggregation lies in its disruption of cellular processes, induction of oxidative stress, and elicitation of immune responses. Recent insights delve into the interplay of genetic, environmental, and cellular factors in amyloid formation and propagation, enhancing our understanding of disease development and progression. Currently, such critical avenues as amyloid overproduction, impaired clearance mechanisms, and the emergence of cerebral amyloid angiopathy are being explored.

The future holds promise in the pursuit of therapeutic interventions that target amyloid aggregation and clearance. Significant progress has been achieved in clinical trials with anti-amyloid antibodies targeting the removal of amyloid from Alzheimer’s disease patients' brains in the past years. These trials come with potential risks, and some remain skeptical about their success.

This Special Issue welcomes the submission of original research manuscripts or review manuscripts which focus on topics which include, but are not limited to:

• Development of novel amyloidosis animal models and comparison of existing ones;
• Reviews about the past, present, and future of anti-amyloid immunotherapies;
• Studies of the molecular mechanisms involved in amyloid overproduction or amyloid clearance in neurodegenerative diseases;
• Longitudinal studies involving amyloid biomarkers;
• Development of CAA in neurodegenerative disorders;
• Amyloid imaging studies in neurodegenerative disease patients;
• Role of glial cells in amyloid production and clearance.

Dr. Angela Gomez-Arboledas
Dr. Giedre Milinkeviciute
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neurodegeneration
• amyloid
• anti-amyloid therapies
• microglia
• astrocytes
• glia
• synapses
• biomarkers
• cognitive decline
• animal models